214 related articles for article (PubMed ID: 31760224)
1. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
[TBL] [Abstract][Full Text] [Related]
2. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
3. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
4. Designing Nanomedicines for Breast Cancer Therapy.
Abbasi Dezfouli S; Rajendran AP; Claerhout J; Uludag H
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892241
[TBL] [Abstract][Full Text] [Related]
5. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
Thapa B; Kc R; Bahniuk M; Schmitke J; Hitt M; Lavasanifar A; Kutsch O; Seol DW; Uludag H
Hum Gene Ther; 2019 Dec; 30(12):1531-1546. PubMed ID: 31547718
[TBL] [Abstract][Full Text] [Related]
6. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
7. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
8. Endocytic Transport of Polyplex and Lipoplex siRNA Vectors in HeLa Cells.
Lazebnik M; Keswani RK; Pack DW
Pharm Res; 2016 Dec; 33(12):2999-3011. PubMed ID: 27585903
[TBL] [Abstract][Full Text] [Related]
9. Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages.
Perez AP; Cosaka ML; Romero EL; Morilla MJ
Int J Nanomedicine; 2011; 6():2715-28. PubMed ID: 22114502
[TBL] [Abstract][Full Text] [Related]
10. From Pulmonary Surfactant, Synthetic KL4 Peptide as Effective siRNA Delivery Vector for Pulmonary Delivery.
Qiu Y; Chow MYT; Liang W; Chung WWY; Mak JCW; Lam JKW
Mol Pharm; 2017 Dec; 14(12):4606-4617. PubMed ID: 29121767
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy.
Remant KC; Thapa B; Valencia-Serna J; Domun SS; Dimitroff C; Jiang X; Uludağ H
J Biomed Mater Res A; 2020 Mar; 108(3):565-580. PubMed ID: 31714657
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.
Sarett SM; Werfel TA; Chandra I; Jackson MA; Kavanaugh TE; Hattaway ME; Giorgio TD; Duvall CL
Biomaterials; 2016 Aug; 97():122-32. PubMed ID: 27163624
[TBL] [Abstract][Full Text] [Related]
13. The role of osmotic polysorbitol-based transporter in RNAi silencing via caveolae-mediated endocytosis and COX-2 expression.
Islam MA; Shin JY; Firdous J; Park TE; Choi YJ; Cho MH; Yun CH; Cho CS
Biomaterials; 2012 Dec; 33(34):8868-80. PubMed ID: 22975426
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).
Mohseni M; Kucharski C; K C RB; Nasrullah M; Jiang X; Uludağ H; Brandwein J
PLoS One; 2021; 16(6):e0251719. PubMed ID: 34157051
[TBL] [Abstract][Full Text] [Related]
15. Endocytosis Controls siRNA Efficiency: Implications for siRNA Delivery Vehicle Design and Cell-Specific Targeting.
Vocelle D; Chan C; Walton SP
Nucleic Acid Ther; 2020 Feb; 30(1):22-32. PubMed ID: 31718426
[TBL] [Abstract][Full Text] [Related]
16. Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo.
Wang J; Xie L; Wang T; Wu F; Meng J; Liu J; Xu H
Acta Biomater; 2017 Sep; 59():158-169. PubMed ID: 28511875
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
Zhang C; Yuan W; Wu Y; Wan X; Gong Y
Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
[TBL] [Abstract][Full Text] [Related]
18. Enhanced gene silencing through human serum albumin-mediated delivery of polyethylenimine-siRNA polyplexes.
Nicolì E; Syga MI; Bosetti M; Shastri VP
PLoS One; 2015; 10(4):e0122581. PubMed ID: 25856158
[TBL] [Abstract][Full Text] [Related]
19. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy.
Li M; Li Y; Huang X; Lu X
J Biomater Sci Polym Ed; 2015; 26(13):813-27. PubMed ID: 26166244
[TBL] [Abstract][Full Text] [Related]
20. Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells.
Parmar MB; K C RB; Löbenberg R; Uludağ H
Biomacromolecules; 2018 Nov; 19(11):4193-4206. PubMed ID: 30222931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
